After demonstrating that SPECT 99mTc-NM-02 imaging can be an accurate and non-invasive method for detecting HER2 status in breast cancer patients, a second trial was activated that also provides for the administration of 188Re-NM-02. This evidence concerns the gene ERBB2 and breast carcinoma.